The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreFeb 2019
US$990Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
A ban on aluminium hydroxide caused the production of antacids to stop altogether in 2014. The government’s ban on this active ingredient can be tied directly to the use of antacids as pepper spray and lachrymator agent (tear gas) blockers during the protests that have taken place in 2014 and 2017.
Whereas the presence of probiotics is not as prevalent so as to cause concern to companies in this category, consumers are now more inclined to purchase remedies that might not suit their needs only because they cannot find the precise item. According to industry sources, there might be some misuse of digestive enzymes and antiflatulents as both influence the digestive process and tend to produce similar results.
Brand owners compete for sales against generics through advertising and solid brand positioning. Generics used to be present only in H2 blockers, with ranitidine, famotidine and cimetidine.
Zuoz Pharma SA as part of Grupo Vargas and Laboratorios Roemmers-Klinos CA are leaders in digestive remedies thanks to increased production of antacids, which had been largely absent from the category since 2014. Zuoz Pharma manufactures Refluxyl – the top brand of digestive remedies – and Titralac, which are some of the limited offerings within antacids that can get around the government’s ban on aluminium hydroxide.
Domestic companies hold modest shares in this concentrated category. Konsuma de Venezuela – as part of Grupo Farma – leads in IBS treatments with its brand Colypan, by filling the void left by the exit of Buscapina (Boehringer Ingelheim CA) and also holds first position in laxatives with Senokot, which has a stronger presence than rival Milax, by CA Productos Ronava.
Laboratorios Behrens CA launched Rehidrosol in November 2017 to become the only oral rehydration electrolyte solution produced entirely in Venezuela. Products in paediatric diarrhoeal remedies vanished after the exit of Abbott Laboratories (Pedialyte) and Merck SA (Florestor) in 2016.
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
Delivery: Files are delivered directly into your account within a few minutes of purchase.
Overview
Discover the latest market trends and uncover sources of future market growth for the Digestive Remedies industry in Venezuela with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Digestive Remedies industry in Venezuela, our research will save you time and money while empowering you to make informed, profitable decisions.
The Digestive Remedies in Venezuela market research report includes:
Our market research reports answer questions such as:
Why buy this report?
This industry report originates from Passport, our Consumer Health market research database.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.